Where can I find 3320.HK's financial statements?

China Resources Pharmaceutical Group Ltd. (3320.HK)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 3320.HK?

China Resources Pharmaceutical Group Ltd. (3320.HK) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 3320.HK update its statements?

China Resources Pharmaceutical Group Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

3320.HK

China Resources Pharmaceutical Group Ltd.

HKSE·Medical, Pharmaceuticals · Healthcare

HK$4.86HK$0.08+1.67%

Market capHK$30.53B·Market closed·Jul 23 8:08 AM UTC

HKD · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	HK$193.24B+14.6%	HK$223.13B+15.5%	HK$270.40B+21.2%	HK$274.18B+1.4%	HK$300.01B+9.4%
Cost of revenue	HK$164.37B+16.2%	HK$188.77B+14.8%	HK$228.41B+21.0%	HK$230.89B+1.1%	HK$250.48B+8.5%
Gross profit	HK$28.87B+6.3%	HK$34.36B+19.0%	HK$42.43B+23.5%	HK$43.30B+2.0%	HK$49.53B+14.4%
Research & development	HK$1.38B+24.3%	HK$1.83B+33.2%	HK$2.73B+48.7%	HK$2.47B−9.3%	HK$3.15B+27.5%
General & administrative	HK$4.16B+5.4%	HK$4.90B+17.8%	HK$6.96B+42.1%	HK$7.16B+2.8%	HK$7.88B+10.1%
Selling & marketing	HK$11.69B+2.9%	HK$14.40B+23.1%	HK$20.80B+44.5%	HK$21.08B+1.3%	HK$24.58B+16.6%
SG&A (combined)	HK$15.85B+3.5%	HK$19.30B+21.7%	HK$27.79B+44.0%	HK$28.26B+1.7%	HK$32.48B+14.9%
Other operating expenses	HK$4.09B+13.0%	HK$3.74B−8.6%	—	−HK$1.25M	—
Total operating expenses	HK$21.32B+6.4%	HK$24.87B+16.6%	HK$30.52B+22.7%	HK$30.73B+0.7%	HK$35.63B+15.9%
Operating income	HK$7.55B+5.9%	HK$9.49B+25.8%	HK$13.90B+46.4%	HK$12.56B−9.6%	HK$13.90B+10.7%
Interest income	HK$595.14M+4.7%	HK$732.22M+23.0%	HK$587.69M−19.7%	HK$681.10M+15.9%	HK$524.87M−22.9%
Interest expense	HK$2.21B−16.6%	HK$2.51B+13.3%	HK$2.39B−4.8%	HK$2.28B−4.4%	HK$2.20B−3.7%
Other income / (expense), net	−HK$685.79M+41.6%	−HK$840.13M−22.5%	−HK$2.97B−253.0%	−HK$931.88M+68.6%	−HK$774.39M+16.9%
Income before tax	HK$6.86B+15.3%	HK$8.65B+26.1%	HK$10.94B+26.4%	HK$11.63B+6.4%	HK$13.13B+12.9%
Income tax expense	HK$1.44B−2.5%	HK$1.77B+23.0%	HK$2.32B+31.1%	HK$2.69B+16.1%	HK$2.38B−11.3%
Net income	HK$3.08B+10.9%	HK$3.64B+18.4%	HK$4.24B+16.4%	HK$3.57B−15.9%	HK$4.50B+26.3%

EPS (basic)	HK$0.49+11.4%	HK$0.55+12.2%	HK$0.68+23.6%	HK$0.56−17.6%	HK$0.72+28.6%
EPS (diluted)	HK$0.49+11.4%	HK$0.55+12.2%	HK$0.68+23.6%	HK$0.56−17.6%	HK$0.72+28.6%
Weighted avg shares (basic)	6,282,510,000	6,282,510,000	6,282,510,000	6,282,510,000	6,287,729,000
Weighted avg shares (diluted)	6,282,510,000	6,282,510,000	6,282,510,000	6,282,510,000	6,282,510,000

Depreciation & amortization	HK$2.30B+12.0%	HK$2.77B+20.2%	HK$3.16B+14.3%	HK$2.70B−14.6%	HK$3.62B+34.1%
EBITDA	HK$9.75B−7.1%	HK$13.59B+39.4%	HK$15.43B+13.6%	HK$15.45B+0.1%	HK$17.70B+14.5%

Frequently Asked Questions About 3320.HK

Where can I find 3320.HK's financial statements?: China Resources Pharmaceutical Group Ltd. (3320.HK)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 3320.HK?: China Resources Pharmaceutical Group Ltd. (3320.HK) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 3320.HK update its statements?: China Resources Pharmaceutical Group Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

HK$193.24B+14.6%

HK$223.13B+15.5%

HK$270.40B+21.2%

HK$274.18B+1.4%

HK$300.01B+9.4%

Cost of revenue

HK$164.37B+16.2%

HK$188.77B+14.8%

HK$228.41B+21.0%

HK$230.89B+1.1%

HK$250.48B+8.5%

Gross profit

HK$28.87B+6.3%

HK$34.36B+19.0%

HK$42.43B+23.5%

HK$43.30B+2.0%

HK$49.53B+14.4%

Research & development

HK$1.38B+24.3%

HK$1.83B+33.2%

HK$2.73B+48.7%

HK$2.47B−9.3%

HK$3.15B+27.5%

General & administrative

HK$4.16B+5.4%

HK$4.90B+17.8%

HK$6.96B+42.1%

HK$7.16B+2.8%

HK$7.88B+10.1%

Selling & marketing

HK$11.69B+2.9%

HK$14.40B+23.1%

HK$20.80B+44.5%

HK$21.08B+1.3%

HK$24.58B+16.6%

SG&A (combined)

HK$15.85B+3.5%

HK$19.30B+21.7%

HK$27.79B+44.0%

HK$28.26B+1.7%

HK$32.48B+14.9%

Other operating expenses

HK$4.09B+13.0%

HK$3.74B−8.6%

—

−HK$1.25M

—

Total operating expenses

HK$21.32B+6.4%

HK$24.87B+16.6%

HK$30.52B+22.7%

HK$30.73B+0.7%

HK$35.63B+15.9%

Operating income

HK$7.55B+5.9%

HK$9.49B+25.8%

HK$13.90B+46.4%

HK$12.56B−9.6%

HK$13.90B+10.7%

Interest income

HK$595.14M+4.7%

HK$732.22M+23.0%

HK$587.69M−19.7%

HK$681.10M+15.9%

HK$524.87M−22.9%

Interest expense

HK$2.21B−16.6%

HK$2.51B+13.3%

HK$2.39B−4.8%

HK$2.28B−4.4%

HK$2.20B−3.7%

Other income / (expense), net

−HK$685.79M+41.6%

−HK$840.13M−22.5%

−HK$2.97B−253.0%

−HK$931.88M+68.6%

−HK$774.39M+16.9%

Income before tax

HK$6.86B+15.3%

HK$8.65B+26.1%

HK$10.94B+26.4%

HK$11.63B+6.4%

HK$13.13B+12.9%

Income tax expense

HK$1.44B−2.5%

HK$1.77B+23.0%

HK$2.32B+31.1%

HK$2.69B+16.1%

HK$2.38B−11.3%

Net income

HK$3.08B+10.9%

HK$3.64B+18.4%

HK$4.24B+16.4%

HK$3.57B−15.9%

HK$4.50B+26.3%

EPS (basic)

HK$0.49+11.4%

HK$0.55+12.2%

HK$0.68+23.6%

HK$0.56−17.6%

HK$0.72+28.6%

EPS (diluted)

HK$0.49+11.4%

HK$0.55+12.2%

HK$0.68+23.6%

HK$0.56−17.6%

HK$0.72+28.6%

Weighted avg shares (basic)

6,282,510,000

6,287,729,000

Weighted avg shares (diluted)

6,282,510,000

Depreciation & amortization

HK$2.30B+12.0%

HK$2.77B+20.2%

HK$3.16B+14.3%

HK$2.70B−14.6%

HK$3.62B+34.1%

EBITDA

HK$9.75B−7.1%

HK$13.59B+39.4%

HK$15.43B+13.6%

HK$15.45B+0.1%

HK$17.70B+14.5%